Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Memorial Sloan-Kettering Cancer Center National Cancer Institute (NCI) |
---|---|
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00006245 |
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
PURPOSE: Phase II trial to study the effectiveness of combining flavopiridol and paclitaxel in treating patients who have locally advanced or metastatic esophageal cancer that has not responded to previous paclitaxel therapy.
Condition | Intervention | Phase |
---|---|---|
Esophageal Cancer |
Drug: alvocidib Drug: paclitaxel |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment |
Official Title: | Phase II Trial of Flavopiridol and Paclitaxel in Patients With Paclitaxel-Refractory Esophageal Cancer |
Study Start Date: | July 2000 |
OBJECTIVES:
OUTLINE: This is a multicenter study.
Patients receive paclitaxel IV over 3 hours on day 1 and flavopiridol IV continuously over 24 hours on day 2 weekly for 3 weeks. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
Quality of life is assessed at baseline, after courses 1 and 2, and then every 2 courses thereafter.
PROJECTED ACCRUAL: A total of 12-37 patients will be accrued for this study within 6-18 months.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Histologically confirmed squamous cell carcinoma or adenocarcinoma of the esophagus or carcinoma of the gastroesophageal (GE) junction
Failed prior combination taxane-based chemotherapy and radiotherapy for locally advanced disease
Must have documented evidence of the following:
Measurable disease
Accurately measured in at least 1 dimension
The following are considered nonmeasurable:
PATIENT CHARACTERISTICS:
Age:
Performance status:
Life expectancy:
Hematopoietic:
Hepatic:
Renal:
Cardiovascular:
Other:
PRIOR CONCURRENT THERAPY:
Biologic therapy:
Chemotherapy:
Endocrine therapy:
Radiotherapy:
Surgery:
Other:
United States, New York | |
Memorial Sloan-Kettering Cancer Center | |
New York, New York, United States, 10021 |
Study Chair: | Gary K. Schwartz, MD | Memorial Sloan-Kettering Cancer Center |
Study ID Numbers: | CDR0000068176, MSKCC-00060, NCI-1672 |
Study First Received: | September 11, 2000 |
Last Updated: | July 23, 2008 |
ClinicalTrials.gov Identifier: | NCT00006245 History of Changes |
Health Authority: | United States: Federal Government |
stage III esophageal cancer stage IV esophageal cancer recurrent esophageal cancer squamous cell carcinoma of the esophagus adenocarcinoma of the esophagus |
Digestive System Neoplasms Gastrointestinal Diseases Esophageal Neoplasms Esophageal Cancer Antimitotic Agents Squamous Cell Carcinoma Protein Kinase Inhibitors Recurrence Carcinoma Flavopiridol Digestive System Diseases |
Paclitaxel Esophageal Disorder Head and Neck Neoplasms Tubulin Modulators Epidermoid Carcinoma Gastrointestinal Neoplasms Esophageal Diseases Carcinoma, Squamous Cell Adenocarcinoma Antineoplastic Agents, Phytogenic |
Digestive System Neoplasms Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Gastrointestinal Diseases Growth Substances Esophageal Neoplasms Physiological Effects of Drugs Mitosis Modulators Enzyme Inhibitors Antimitotic Agents Protein Kinase Inhibitors Pharmacologic Actions |
Flavopiridol Neoplasms Digestive System Diseases Neoplasms by Site Paclitaxel Therapeutic Uses Head and Neck Neoplasms Tubulin Modulators Gastrointestinal Neoplasms Growth Inhibitors Esophageal Diseases Antineoplastic Agents, Phytogenic |